105p 2.5 2.4%
Last Trade - 29/05/20
| Market Cap | £26.7m |
| Enterprise Value | £25.7m |
| Revenue | £3.28m |
| Position in Universe | 1285th / 1825 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 31st Dec | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | TTM | 2020E | 2021E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|---|
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2020
|
31st Dec 2021
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
Fusion Antibodies PLC, formerly Fusion Antibodies, Ltd., is a United Kingdom-based cancer therapeutics developer. The Company develops and commercializes antibody-based therapeutics for cancer. The Company develops a range of antibody engineering services based around monoclonal antibodies. It focuses in the expression and purification of recombinant proteins and chimeric antibodies for the research, diagnostic and therapeutic markets. Its technology generates target specific antibodies from protein antigens. The Company's therapeutic and diagnostic research and development are offered as a service to pharmaceutical, biopharmaceutical and academic researchers.
| Last Annual | March 31st, 2019 |
| Last Interim | September 30th, 2019 |
| Incorporated | November 29, 2000 |
| Public Since | December 18, 2017 |
| No. of Shareholders: | n/a |
| No. of Employees: | 30 |
| Sector | Healthcare |
| Industry | Biotechnology & Medical Research |
| Index | FTSE Aim All Share , |
| Exchange | London Stock Exchange (AIM) |
| Shares in Issue | 25,424,525 |
| Free Float | (0.0%) |
| Eligible for |
ISAs
SIPPs
|
| Address | Springbank Industrial Estate,1 Springbank Road, BELFAST, BT17 0QL, United Kingdom |
| Web | https://fusionantibodies.com/ |
| Phone | +44 28 90432800 |
| Auditors | PricewaterhouseCoopers LLP |
As of 29/05/20, shares in Fusion Antibodies are trading at 105p, giving the company a market capitalisation of £26.7m. This share price information is delayed by 15 minutes.
Shares in Fusion Antibodies are currently trading at 105p and the price has moved by 82.61% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Fusion Antibodies price has moved by 0.108k% over the past year.
Of the analysts with advisory recommendations for Fusion Antibodies, there are there are currently "buy" , "hold" and "sell" recommendations. The overall consensus recommendation for Fusion Antibodies is Not available. You can view the full broker recommendation list by unlocking its StockReport.
Fusion Antibodies is scheduled to issue upcoming financial results on the following dates:
Fusion Antibodies does not currently pay a dividend.
Fusion Antibodies does not currently pay a dividend.
Fusion Antibodies does not currently pay a dividend.
To buy shares in Fusion Antibodies you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in Fusion Antibodies are currently trading at 105p, giving the company a market capitalisation of £26.7m.
Here are the trading details for Fusion Antibodies:
Based on an overall assessment of its quality, value and momentum, Fusion Antibodies is currently classified as a Style Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We were not able to load any forecast data for Fusion Antibodies.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Fusion Antibodies. Over the past six months, the relative strength of its shares against the market has been 64.38%. At the current price of 105p, shares in Fusion Antibodies are trading at 28.72% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We were not able to find PE ratio data for Fusion Antibodies.
Fusion Antibodies's management team is headed by:
Here are the top five shareholders of Fusion Antibodies based on the size of their shareholding:
